Moukadem Hiba A, Fakhreddine Mohammad A, Assaf Nada, Safi Nadine, Al Masry Ahmad, Al Darazi Monita, Mahfouz Rami, El Saghir Nagi S
Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon.
Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut 1001, Lebanon.
World J Clin Oncol. 2024 Dec 24;15(12):1481-1490. doi: 10.5306/wjco.v15.i12.1481.
The prevalence of germline pathogenic variants in high hereditary risk breast and/or ovarian cancer patients and unaffected subjects referred for testing is an unmet need in low and middle-income countries.
To determine the prevalence of germline pathogenic variants in high hereditary risk patients with breast and/or ovarian cancer and unaffected individuals.
We retrospectively reviewed records of patients and unaffected subjects referred for germline pathogenic variant testing due to high hereditary risk between 2010-2020. Data was collected and analyzed on Excel sheet.
In total, 358 individuals were included, including 257 patients and 101 unaffected individuals with relatives with breast or ovarian cancer. The prevalence of pathogenic variants was 8.63% (19/220) in patients with breast cancer, and 15.1% (5/33) in those with ovarian cancer. Among the 25 of 220 patients with breast cancer tested by next-generation sequencing, 3 patients had pathogenic variants other than . The highest risk was observed in those aged 40 years with breast cancer and a positive family history, where the prevalence was 20.1% (9/43). Among the unaffected subjects, 31.1% (14/45) had the same pathogenic variants in their corresponding relatives. Among the subjects referred because of a positive family history of cancer without known hereditary factors, 5.35% (3/56) had pathogenic variants of and . The c.131G>T nucleotide change was noted in one patient and two unrelated unaffected subjects with a pathogenic variant.
This study showed a 8.63% prevalence of pathogenic variants in patients with breast cancer and a 15.1% prevalence in patients with ovarian cancer. Among the relatives of patients with pathogenic variants, 31% tested positive for the same variant, while 5.3% of subjects who tested positive due to a family history of breast cancer had a pathogenic variant.
在中低收入国家,对高遗传风险乳腺癌和/或卵巢癌患者以及接受检测的未患病个体中,种系致病变异的流行情况是一个尚未满足的需求。
确定高遗传风险乳腺癌和/或卵巢癌患者以及未患病个体中种系致病变异的流行情况。
我们回顾性分析了2010年至2020年间因高遗传风险而接受种系致病变异检测的患者和未患病个体的记录。数据在Excel表格中收集和分析。
总共纳入了358人,包括257例患者和101名有乳腺癌或卵巢癌亲属的未患病个体。乳腺癌患者中致病变异的流行率为8.63%(19/220),卵巢癌患者中为15.1%(5/33)。在220例接受下一代测序检测的乳腺癌患者中,有25例,其中3例有除[具体基因名称]之外的致病变异。在40岁且有乳腺癌家族史的患者中观察到最高风险,其流行率为20.1%(9/43)。在未患病个体中,31.1%(14/45)在其相应亲属中有相同的[具体基因名称]致病变异。在因癌症家族史阳性但无已知遗传因素而转诊的个体中,5.35%(3/56)有[具体基因名称]和[具体基因名称]的致病变异。在一名患者以及两名有[具体基因名称]致病变异的无关未患病个体中发现了c.131G>T核苷酸变化。
本研究显示乳腺癌患者中致病变异的流行率为8.63%,卵巢癌患者中为15.1%。在有[具体基因名称]致病变异患者的亲属中,31%检测出相同变异呈阳性,而因乳腺癌家族史检测呈阳性的个体中有5.3%有[具体基因名称]致病变异。